ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of “Buy” from Brokerages

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has received a consensus rating of “Buy” from the four ratings firms that are currently covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $82.75.

Several equities research analysts have commented on the stock. Capital One Financial began coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 15th. They set an “overweight” rating and a $80.00 price target on the stock. HC Wainwright increased their price target on ANI Pharmaceuticals from $87.00 to $94.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Guggenheim restated a “buy” rating and issued a $77.00 price target on shares of ANI Pharmaceuticals in a research note on Tuesday, April 23rd.

ANI Pharmaceuticals Stock Up 0.9 %

NASDAQ:ANIP opened at $63.68 on Friday. The stock has a 50-day simple moving average of $64.22 and a 200 day simple moving average of $61.76. ANI Pharmaceuticals has a 52-week low of $48.20 and a 52-week high of $70.81. The company has a market cap of $1.34 billion, a PE ratio of 39.80 and a beta of 0.81. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.12 and a current ratio of 3.95.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, May 10th. The specialty pharmaceutical company reported $0.95 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.16. ANI Pharmaceuticals had a net margin of 6.87% and a return on equity of 17.15%. The company had revenue of $137.43 million for the quarter, compared to the consensus estimate of $125.01 million. On average, sell-side analysts expect that ANI Pharmaceuticals will post 3.37 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Chad Gassert sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $67.25, for a total value of $1,345,000.00. Following the completion of the sale, the senior vice president now directly owns 253,226 shares of the company’s stock, valued at $17,029,448.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, SVP Ori Gutwerg sold 2,985 shares of the firm’s stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $67.00, for a total transaction of $199,995.00. Following the completion of the sale, the senior vice president now owns 77,227 shares in the company, valued at approximately $5,174,209. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Chad Gassert sold 20,000 shares of ANI Pharmaceuticals stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $67.25, for a total transaction of $1,345,000.00. Following the sale, the senior vice president now directly owns 253,226 shares of the company’s stock, valued at approximately $17,029,448.50. The disclosure for this sale can be found here. Insiders have sold a total of 176,688 shares of company stock valued at $11,408,863 over the last 90 days. 12.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. Pacer Advisors Inc. acquired a new position in shares of ANI Pharmaceuticals in the fourth quarter valued at approximately $41,000. AJOVista LLC acquired a new position in ANI Pharmaceuticals in the 4th quarter valued at $58,000. SG Americas Securities LLC bought a new position in ANI Pharmaceuticals during the 1st quarter worth $106,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of ANI Pharmaceuticals by 361.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,367 shares of the specialty pharmaceutical company’s stock worth $131,000 after buying an additional 1,854 shares in the last quarter. Finally, ADAR1 Capital Management LLC bought a new stake in shares of ANI Pharmaceuticals in the fourth quarter valued at about $132,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.